Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26674860 | 1.00 | UTS2R (0.43) | UTS2RGRM4KDM4EGAALRRK2 | |
| SCHEMBL31441739 | 0.93 | KDM4E (0.47) | UTS2RGRM4KDM4EGAALRRK2 | |
| SCHEMBL15206197 | 0.92 | MERTK (0.45) | ADORA2A | |
| SCHEMBL35212475 | 0.88 | MAPK1 (0.57) | LRRK2MAPK1PDE10AHIPK2IRAK4 | |
| SCHEMBL25011517 | 0.80 | JAK3 (0.55) | IRAK4 | |
| SCHEMBL6890946 | 0.77 | HTR3A (0.63) | IRAK4 | |
| SCHEMBL6887637 | 0.77 | HTR3A (0.63) | IRAK4 | |
| SCHEMBL5958267 | 0.77 | UTS2R (0.43) | UTS2RGRM4KDM4EGAALRRK2 | |
| SCHEMBL14818705 | 0.77 | PDE10A (0.56) | UTS2RGRM4KDM4EGAALRRK2 | |
| SCHEMBL29350072 | 0.77 | GAA (0.46) | UTS2RGRM4KDM4EGAALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| CN-119894872-A | Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof | 修复治疗公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | UTS2R 3262/4885GRM4 3835/4885KDM4E 3245/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | UTS2R 2839/4885GRM4 3364/4885KDM4E 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.